Monday, September 10, 2018 Please be aware that two trials have recently been permenantly closed: MAC8 (NSABP B-37): A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer. HEC1 (CALGB 80802): Phase III Randomized Study of Sorafenib Plus Doxorubicin versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC). If you have any questions please contact Christine Bertrim, Trial Management Associate
